Lancet oncol:卡博替尼治疗铂耐药的转移性尿路上皮癌

2020-07-12 QQY MedSci原创

卡博替尼是MET、VEGFR、AXL和RET的多激酶抑制剂,对由调节T细胞和髓系来源抑制细胞减少引起的肿瘤免疫微环境同样有效。在本研究中,研究人员评估了卡博替尼用于转移性铂-复发的移行上皮细胞癌的活性

卡博替尼是MET、VEGFR、AXL和RET的多激酶抑制剂,对由调节T细胞和髓系来源抑制细胞减少引起的肿瘤免疫微环境同样有效。在本研究中,研究人员评估了卡博替尼用于转移性铂-复发的移行上皮细胞癌的活性。

本研究是一项开放的、单臂的、3个队列的2期试验,招募年满18岁的组织学确诊的尿路上皮癌或罕见类型的、Karnofsky表现量表指数≥60%,且至少既往行过一次铂类化疗(铂耐药)后病程进展的患者。予以卡博替尼 60 mg 口服 1/日,28天一疗程,直到病程进展或出现不可耐受的毒性。主要终点是队列1中的客观缓解率(根据RECIST评估)

2012年9月28日-2015年10月20日,共招募了68位患者(队列1、2和3分别有49人、6人和13人)。所有患者至少接受一剂量卡博替尼。57位可进行缓解评估的患者的中位随访时间为61.2个月(IQR 53.8-70.0)。在队列1可评估的42位患者中,有一例完全缓解和7例部分缓解(客观缓解率为19%,95% CI 9-34)。最常见的3-4级不良反应有疲劳(6例[9%])、高血压(5[7%])、蛋白尿(4[6%])和低磷血症(4[6%])。无治疗相关死亡。

卡博替尼用于严重预处理的、铂难治的转移性尿路上皮癌患者中具有单药临床活性,且通常具有良好的耐受性。卡博替尼具有先天和适应性的免疫调节特性,这为将其与免疫治疗策略结合提供了理论基础。

原始出处:

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
    2020-09-26 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
    2021-02-03 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
    2020-07-13 lovetcm

    #卡博替尼#肿瘤治疗的第三道防线。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
    2020-07-13 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1830736, encodeId=8c001830e364c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 26 22:12:33 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865864, encodeId=5d181865864ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Feb 03 03:12:33 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737647, encodeId=798d1e37647cd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 09 05:12:33 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93413, encryptionId=d1559341310, topicName=转移性尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Tue Jul 14 13:12:33 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802689, encodeId=c6a4802689fd, content=<a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a>肿瘤治疗的第三道防线。, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36491, encryptionId=01a536491b9, topicName=卡博替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jul 13 21:00:47 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033880, encodeId=0c3e1033880d5, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038065, encodeId=f5b0103806580, content=谢谢williamhill asia 分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 13 01:12:33 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
    2020-07-13 anti-cancer

    谢谢williamhill asia 分享这么多精彩信息

    0

相关威廉亚洲官网

J Clin Oncol:晚期肾癌新药卡博替尼:能否兼顾生命的长度和质量?

METEOR研究(NCT01865747)是2016年晚期肾癌(RCC)领域的一项重磅研究。对既往接受过至少1种VEGFR-TKI治疗并在6个月内进展的晚期RCC患者,卡博替尼显示了生存的获益。但关于晚期RCC的治疗,生活质量同样是非常重要的。那么卡博替尼治疗的患者生活质量如何呢?

深观察|聊城卡博替尼案:怎样才能不重演“我不是药神”?

近日,山东聊城市肿瘤医院医生向患者推荐抗癌药卡博替尼,却被当成“假药案”处理的事,引发了社会广泛关注。根据聊城市卫健委的《情况通报》,该市肿瘤医院陈宗祥医师向患有小细胞肺癌且出现化疗药耐药的患者,推荐了国内尚未上市的靶向药卡博替尼(Cabozantinib Tablets),在病人家属购药无门的情形之下,陈宗祥为病人亲属提供购买渠道(病友互助购买)。遗憾的是,病人服药后出现严重恶心呕吐、虚弱,并最

卡博替尼有望成为放射性碘拮抗的甲状腺癌一线治疗药物

可阻断涉及髓样癌细胞发生和发展的异常激酶蛋白的激酶抑制剂卡博替尼(cabozantinib)被证明对于转移性放射性碘拮抗的甲状腺癌患者仍然有效。

NEJM:卡博替尼治疗晚期和进展性肝细胞癌

由此可见,在既往治疗过的晚期肝细胞癌患者中,与安慰剂相比,使用卡博替尼治疗可获得更长的总生存期和无进展生存期。卡博替尼组中高级别不良事件的发生率约为安慰剂组的两倍。

聚焦聊城“假药门” 带你揭露假药真相

2月25日,山东新闻联播《今日聚焦》播出的一位肿瘤医生开具抗癌药经食药监部门鉴定属于假药一事引发关注。 以下是来源于北京头条的事件始末: 近日,聊城市民王玉青反映,其父亲在聊城市肿瘤医院治疗期间,主治医生陈宗祥给推荐了一款名为"卡博替尼"(Cabozantinib Tablets)的印度仿制抗癌药,并将药名写入医嘱单。 王玉青从陈宗祥医生推荐的第三者手中买到两盒"卡博替尼",每盒

Lancet oncol:卡博替尼用于高度恶性的尤文肉瘤和骨肉瘤的疗效和安全性

尤文肉瘤或骨肉瘤患者在确诊后的中位总生存期不到12个月,目前尚无标准疗法。在几个尤文肉瘤和肉瘤的预临床模型中,药理抑制MET信号和异常血管生成展现出一定治疗效果。研究人员开展一多中心的、单臂、两阶段的2期试验,招募年满12岁的ECOG表现状态0-1分的晚期尤文肉瘤或骨肉瘤患者,以评估MET和VEGFR2抑制剂卡博替尼(cabozantinib)用于这两种肿瘤的活性。予以卡博替尼(成人 60mg、儿